Literature DB >> 26797519

Association Between Tumor Necrosis Factor-α and Diabetic Peripheral Neuropathy in Patients with Type 2 Diabetes: a Meta-Analysis.

Ze-Peng Mu1, Yan-Gang Wang2, Cheng-Qian Li1, Wen-Shan Lv1, Bin Wang1, Zhao-Hai Jing1, Xue-Jia Song1, Yu Lun1, Ming-Yue Qiu1, Xiao-Long Ma1.   

Abstract

Tumor necrosis factor-α (TNF-α) is a cell signaling protein involved in systemic inflammation, and is also an important cytokine in the acute phase reaction. Several studies suggested a possible association between TNF-α and diabetic peripheral neuropathy (DPN) in type 2 diabetic patients, but no accurate conclusion was available. A systematic review and meta-analysis of observational studies was performed to comprehensively assess the association between serum TNF-α levels and DPN in type 2 diabetic patients. We searched Pubmed, Web of Science, Embase, and China Biology Medicine (CMB) databases for eligible studies. Study-specific data were combined using meta-analysis. Fourteen studies were finally included into the meta-analysis, which involved a total of 2650 participants. Meta-analysis showed that there were obviously increased serum TNF-α levels in DPN patients compared with type 2 diabetic patients without DPN (standard mean difference [SMD] = 1.203, 95 % CI 0.795-1.611, P < 0.001). There were also obviously increased levels of serum TNF-α in diabetic patients with DPN when compared with healthy controls (SMD = 2.364, 95 % CI 1.333-3.394, P < 0.001). In addition, there were increased serum TNF-α levels in painful DPN patients compared with painless DPN patients (SMD = 0.964, 95 % CI 0.237-1.690, P = 0.009). High level of serum TNF-α was significantly associated with increased risk of DPN in patients with type 2 diabetes (odds ratio [OR] = 2.594, 95 % CI 1.182-5.500, P = 0.017). Increased serum levels of TNF-α was not associated with increased risk of painful DPN in patients with type 2 diabetes (OR = 2.486, 95 % CI 0.672-9.193, P = 0.172). Sensitivity analysis showed that there was no obvious change in the pooled estimates when omitting single study by turns. Type 2 diabetic patients with peripheral neuropathy have obviously increased serum TNF-α levels than type 2 diabetic patients without peripheral neuropathy and healthy controls, and high level of serum TNF-α may be associated with increased risk of peripheral neuropathy independently. Further prospective cohort studies are needed to assess the association between TNF-α and DPN.

Entities:  

Keywords:  Diabetic peripheral neuropathy; Meta-analysis; Tumor necrosis factor-α

Mesh:

Substances:

Year:  2016        PMID: 26797519     DOI: 10.1007/s12035-016-9702-z

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  60 in total

1.  Activation of IL-1 signaling pathway in Schwann cells during diabetic neuropathy.

Authors:  Dusanka S Skundric; Rujuan Dai; Jascinth James; Robert P Lisak
Journal:  Ann N Y Acad Sci       Date:  2002-04       Impact factor: 5.691

2.  Bone marrow-derived TNF-α causes diabetic neuropathy in mice.

Authors:  Hiroshi Urabe; Tomoya Terashima; Fan Lin; Hideto Kojima; Lawrence Chan
Journal:  Diabetologia       Date:  2014-11-16       Impact factor: 10.122

3.  Molecular mechanisms of tumor necrosis factor alpha gene expression in monocytic cells via hyperglycemia-induced oxidant stress-dependent and -independent pathways.

Authors:  M Guha; W Bai; J L Nadler; R Natarajan
Journal:  J Biol Chem       Date:  2000-06-09       Impact factor: 5.157

4.  Association between cardiac autonomic dysfunction and inflammation in type 1 diabetic patients: effect of beta-blockade.

Authors:  Gaetano Antono Lanza; Dario Pitocco; Eliano Pio Navarese; Alfonso Sestito; Gregory Angelo Sgueglia; Andrea Manto; Fabio Infusino; Tittania Musella; Giovanni Ghirlanda; Filippo Crea
Journal:  Eur Heart J       Date:  2007-03-19       Impact factor: 29.983

5.  Role of MCP-1 in tumor necrosis factor-alpha-induced endothelial dysfunction in type 2 diabetic mice.

Authors:  Jiyeon Yang; Yoonjung Park; Hanrui Zhang; Xue Gao; Emily Wilson; Warren Zimmer; Louise Abbott; Cuihua Zhang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-08-07       Impact factor: 4.733

6.  Toll-like receptor 4 and tumor necrosis factor-alpha as diagnostic biomarkers for diabetic peripheral neuropathy.

Authors:  Tao Zhu; Qingsheng Meng; Jian Ji; Xiaoli Lou; Lijuan Zhang
Journal:  Neurosci Lett       Date:  2014-11-17       Impact factor: 3.046

7.  Systemic and spinal administration of etanercept, a tumor necrosis factor alpha inhibitor, blocks tactile allodynia in diabetic mice.

Authors:  Ahmet Dogrul; Husamettin Gul; Ozgur Yesilyurt; Umit H Ulas; Oguzhan Yildiz
Journal:  Acta Diabetol       Date:  2010-11-23       Impact factor: 4.280

8.  Peripheral neuropathy is associated with increased serum levels of uric acid in type 2 diabetes mellitus.

Authors:  N Papanas; N Katsiki; K Papatheodorou; M Demetriou; D Papazoglou; T Gioka; E Maltezos
Journal:  Angiology       Date:  2011-02-08       Impact factor: 3.619

9.  Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics.

Authors:  K Van Acker; D Bouhassira; D De Bacquer; S Weiss; K Matthys; H Raemen; C Mathieu; I M Colin
Journal:  Diabetes Metab       Date:  2009-03-17       Impact factor: 6.041

Review 10.  Interrelation of oxidative stress and inflammation in neurodegenerative disease: role of TNF.

Authors:  Roman Fischer; Olaf Maier
Journal:  Oxid Med Cell Longev       Date:  2015-03-05       Impact factor: 6.543

View more
  15 in total

Review 1.  The crosstalk among TLR2, TLR4 and pathogenic pathways; a treasure trove for treatment of diabetic neuropathy.

Authors:  Seyed Hossein Aghamiri; Khalil Komlakh; Mehran Ghaffari
Journal:  Inflammopharmacology       Date:  2022-01-12       Impact factor: 4.473

2.  A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain.

Authors:  Emily Pickering; Elizabeth L Steels; Kathryn J Steadman; Amanda Rao; Luis Vitetta
Journal:  Inflammopharmacology       Date:  2022-09-04       Impact factor: 5.093

3.  Transcriptional networks of progressive diabetic peripheral neuropathy in the db/db mouse model of type 2 diabetes: An inflammatory story.

Authors:  Lucy M Hinder; Benjamin J Murdock; Meeyoung Park; Diane E Bender; Phillipe D O'Brien; Amy E Rumora; Junguk Hur; Eva L Feldman
Journal:  Exp Neurol       Date:  2018-03-14       Impact factor: 5.330

4.  LncRNA-MEG3 Regulates the Inflammatory Responses and Apoptosis in Porcine Alveolar Macrophages Infected with Haemophilus parasuis Through Modulating the miR-210/TLR4 Axis.

Authors:  Rong H Yin; Zhong B Guo; Yuan Y Zhou; Chao Wang; Rong L Yin; Wen L Bai
Journal:  Curr Microbiol       Date:  2021-06-30       Impact factor: 2.188

5.  TNF-Alpha in Peripheral Neuropathy Patients with Impaired Glucose Regulation.

Authors:  Xia Li; Ju Zhu; Na Liu; Jie Liu; Zhecheng Zhang
Journal:  J Diabetes Res       Date:  2017-01-30       Impact factor: 4.011

Review 6.  Interactions between and Shared Molecular Mechanisms of Diabetic Peripheral Neuropathy and Obstructive Sleep Apnea in Type 2 Diabetes Patients.

Authors:  Hong Shen; Junrong Zhao; Ying Liu; Guangdong Sun
Journal:  J Diabetes Res       Date:  2018-07-19       Impact factor: 4.011

7.  Network Pharmacology and Molecular Docking Study on the Potential Mechanism of Yi-Qi-Huo-Xue-Tong-Luo Formula in Treating Diabetic Peripheral Neuropathy.

Authors:  Yixuan Lin; Chuqiao Shen; Fanjing Wang; Zhaohui Fang; Guoming Shen
Journal:  J Diabetes Res       Date:  2021-05-28       Impact factor: 4.011

8.  Dietary Reversal Ameliorates Short- and Long-Term Memory Deficits Induced by High-fat Diet Early in Life.

Authors:  Catrina Sims-Robinson; Anna Bakeman; Elizabeth Bruno; Samuel Jackson; Rebecca Glasser; Geoffrey G Murphy; Eva L Feldman
Journal:  PLoS One       Date:  2016-09-27       Impact factor: 3.240

9.  Involvement of microRNA-146a in diabetic peripheral neuropathy through the regulation of inflammation.

Authors:  Yonghao Feng; Long Chen; Qiong Luo; Men Wu; Yinghui Chen; Xiaohong Shi
Journal:  Drug Des Devel Ther       Date:  2018-01-17       Impact factor: 4.162

10.  Targeting soluble tumor necrosis factor as a potential intervention to lower risk for late-onset Alzheimer's disease associated with obesity, metabolic syndrome, and type 2 diabetes.

Authors:  Maria Elizabeth De Sousa Rodrigues; Madelyn C Houser; Douglas I Walker; Dean P Jones; Jianjun Chang; Christopher J Barnum; Malú G Tansey
Journal:  Alzheimers Res Ther       Date:  2019-12-31       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.